What Huvepharma does

Huvepharma AD is a Bulgaria-headquartered pharmaceutical and animal health company founded in 1999 that develops, manufactures, and markets products for human and animal health applications. The company operates through its wholly-owned subsidiary Biovet AD, which runs one of Europe's largest fermentation facilities with over 9 million liters of installed capacity in Sofia, Bulgaria. Its core technology platform is precision fermentation at industrial scale, leveraged both for proprietary products (such as Bio D®, a vitamin D supplement for animal nutrition with claimed superior bioavailability of 83% absorption versus 66% for conventional vitamin D) and for contract manufacturing services provided to biotech and food-tech companies.

The company operates a B2B go-to-market model with two primary revenue streams: contract manufacturing services for precision fermentation products (exemplified by its strategic manufacturing partnership with The EVERY Company to produce OvoPro™, the world's first commercially available precision-fermented egg protein, with end products distributed through major retailers including Target and Walmart) and direct sales of proprietary animal nutrition products to livestock and poultry producers. Huvepharma's customer base spans enterprise biotech and food-tech firms requiring industrial-scale fermentation manufacturing, as well as animal feed producers seeking differentiated nutritional inputs. Leadership includes President Glen Wilkinson, CFO Darius Gazinschi, and Anton Ivanov Nakov as Chief of Chemistry Division.

The business is supported by 1,001–5,000 employees and a privately held ownership structure with no disclosed parent or institutional investors. Recent strategic activity has been concentrated on scaling the contract manufacturing platform, including a 4x production capacity expansion announced in June 2026 driven by 550% year-over-year order growth from The EVERY Company, and the launch of Bio D® in February 2026. No public pricing information or financial metrics are disclosed.

Name

Huvepharma

Legal name

Huvepharma

Website

https://huvepharma.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Huvepharma is a Bulgaria-based pharmaceutical and animal health company that develops and manufactures human and animal health products, operating one of Europe's largest precision fermentation facilities via subsidiary Biovet AD to serve livestock producers and biotech/food-tech clients.

Ownership category

akta.pro rank

Product category

Animal Health & Nutrition Pharmaceuticals

NAICS

Animal Food Manufacturing (3111), Food Manufacturing (311)

SIC

Food And Kindred Products (2000), Agricultural Prod-Livestock & Animal Specialties (200)

akta.pro primary industry

Manufacturing, Private Label & Co-Manufacturing for Animal Diets (HLAMAHAO)

akta.pro secondary industries

Non-Antibiotic Health & Performance Supplements (Immune, Gut Health, Stress/Heat Support) (AFADALAO), Plant-Based & Alternative Proteins (Packaged) (CRADAAAH)

Keywords

• Animal health products
• Animal nutrition supplements
• Precision fermentation manufacturing
• Vitamin D supplements
• Human and veterinary pharmaceuticals

Headquarters

HQ city

Sofia

HQ country

Bulgaria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel, Infrastructure

Revenue model

1. Contract Manufacturing Services: Provides manufacturing services for biotech and food-tech companies requiring large-scale precision fermentation capabilities, including production of recombinant proteins and specialty ingredients
2. Animal Nutrition Products: Sells proprietary feed additives and vitamin supplements for animal nutrition, including Bio D® vitamin D products for livestock and poultry

Go-to-market motion1 record

Distribution channels1 record

Core offering

Huvepharma develops, manufactures, and markets human and animal health products, with a core focus on fermentation-based animal nutrition supplements (such as Bio D® vitamin D) and contract precision-fermentation manufacturing services delivered through its Bulgaria-based subsidiary Biovet AD. The company leverages one of Europe's largest fermentation facilities (over 9 million liters of installed capacity) to produce bio-based ingredients for the animal health, nutrition, and food technology industries.

Product overview

Huvepharma is a pharmaceutical and animal nutrition company offering fermentation-based products primarily for animal health and nutrition. The core product portfolio includes Bio D®, a vitamin D supplement for animal nutrition produced via controlled fermentation with superior bioavailability claims, alongside manufacturing infrastructure through its Biovet AD subsidiary in Bulgaria (one of Europe's largest fermentation facilities with over 9 million liters capacity). The company also provides contract manufacturing services, including precision fermentation capabilities as demonstrated in its partnership with The EVERY Company for OvoPro™ production.

Differentiator

Problem solved

Functional benefit

Brands

• Bio D®: Vitamin D supplement for animal nutrition produced through controlled fermentation process, claimed to offer superior bioavailability (83% absorption vs 66% for conventional vitamin D, 93% retention vs 80%)

Products and services

• Bio D®
• Precision Fermentation Contract Manufacturing Services

Quantifiable outcome

• Bio D® demonstrates 83% absorption versus 66% for conventional vitamin D sources
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• The EVERY CompanycoreStrategic or Co-development Partner · 15 June 2026Strategic manufacturing partnership for OvoPro™ production - the world's first commercially available egg protein made via precision fermentation. Huvepharma's subsidiary Biovet AD is quadrupling production capacity at its Bulgaria facility to meet surging demand, with The EVERY Company securing orders worth 550% of its 2025 volume in just the first four months of 2026. Products are distributed through major retail channels including Target and Walmart.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Emerging players

• Perfect Day: Precision-fermentation company producing animal-free dairy proteins; comparable to Huvepharma's OvoPro™ contract-manufacturing work for The EVERY Company as an emerging alt-protein fermentation brand.
• Geltor: Precision-fermentation startup producing animal-free proteins for food, beauty, and nutrition — adjacent emerging peer to Huvepharma's Biovet AD in commercializing fermentation-derived proteins at scale.

Broad incumbents

• Lesaffre: Global yeast and fermentation specialist producing ingredients for food, nutrition, and animal feed — comparable to Huvepharma as a privately held, fermentation-focused manufacturer with adjacent animal-nutrition exposure.
• DSM-Firmenich: Global nutrition and health group with a sizable animal-nutrition and precision-fermentation footprint (including vitamins and feed additives) — directly overlaps Huvepharma's fermentation-derived Bio D® vitamin D business and broader ingredient strategy.
• Zoetis: Largest global animal-health company with broad pharmaceutical, vaccine, and nutrition portfolios serving livestock producers and veterinarians — overlaps with Huvepharma's animal-nutrition offerings as a much larger incumbent.
• Novonesis: Major industrial fermentation specialist (formed from Novozymes and Chr. Hansen) producing enzymes, probiotics, and fermentation-derived ingredients — comparable to Huvepharma in large-scale fermentation capability and contract manufacturing.
• ADM: Global nutrition and ingredient company with substantial fermentation and animal-nutrition businesses; comparable to Huvepharma in precision-fermentation-based ingredient manufacturing and feed-additive distribution.
• Cargill: Privately held global agribusiness with a large animal-nutrition business and significant fermentation capabilities — comparable to Huvepharma as a broad animal-feed additive and ingredient manufacturer.

Direct peers

• Elanco Animal Health: Large pure-play animal health company offering pharmaceuticals, vaccines, and feed additives across livestock and companion animals; directly comparable to Huvepharma's animal-health product set.
• Phibro Animal Health: Public animal health and nutrition company producing feed additives, vaccines, and nutritional specialty products for livestock and poultry — directly comparable to Huvepharma's Bio D® and broader animal-nutrition franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/huvepharma-nv

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Huvepharma